Epidermal Growth Factor Receptor as a Therapeutic Target in Lung Cancer

Almost two decades of research to determine how cancer cells differ from noncancerous cells at the molecular level have been richly rewarding. Several molecular growth factors and receptors have been discovered that play a role in tumor development and are differentially expressed in tumor cells. In this regard, the structure and function of the epidermal growth factor receptor (EGFR) have been characterized. Efforts to develop effective anticancer therapy have targeted this receptor because it is critical to tumor cell proliferation, survival, and invasiveness. Overexpression of EGFR occurs in several epithelial cell tumors, including non-small cell lung cancer (NSCLC). Small-molecular-weight EGFR tyrosine kinase inhibitors and EGFR monoclonal antibodies are among the agents that have demonstrated activity against NSCLC. These compounds, which are designed to selectively target tumor cells, represent a new and novel treatment approach that is being evaluated in NSCLC clinical trials.

Epidermal growth factor receptor (EGFR) - tyrosine kinase - non-small cell lung cancer (NSCLC) - ZD1839 - IMC-C225

REFERENCES

• 1 American Cancer Society .Cancer Facts and Figures, 2003. Atlanta, GA; American Cancer Society 2003
• 2 Pisters K M. Adjuvant and neoadjuvant therapy for early stage non-small cell lung cancer.  Semin Oncol. 2001;  28(suppl 14) S23-S28
• 3 Shepherd F A, Fossella F V, Lynch T et al.. Docetaxel (taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials.  Semin Oncol. 2001;  28(suppl 2) S4-S9
• 4 Chang A Y, Kim K, Glick J et al.. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results.  J Natl Cancer Inst. 1993;  85 388-394
• 5 Roszkowski K, Pluzanska A, Krzakowski M et al.. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or nonresectable localized non-small cell lung cancer (NSCLC).  Lung Cancer. 2000;  27 145-157
• 6 Abratt R P, Bexwoda W R, Falkson G et al.. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.  J Clin Oncol. 1994;  12 1535-1540
• 7 Depierre A, Lemarie E, Dabouis G et al.. A phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer.  Am J Clin Oncol. 1991;  14 115-119
• 8 Ranson M, Davidson N, Nicholson M et al.. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.  J Natl Cancer Inst. 2000;  92 1074-1080
• 9 Anderson H, Hopwood P, Stephens R J et al.. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.  Br J Cancer. 2000;  83 447-453
• 10 Bunn Jr P A. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?.  J Clin Oncol. 2002;  20 S23-S33
• 11 Herbst R S, Langer C J. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.  Semin Oncol. 2002;  29(suppl 4) S27-S36
• 12 Ethier S P. Signal transduction pathways: the molecular basis for targeted therapies.  Semin Radiat Oncol. 2002;  12(suppl 2) S3-S10
• 13 Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy.  Oncogene. 2000;  19 6550-6565
• 14 Ferreira C G, Huisman C, Giaccone G. Novel approaches to the treatment of non-small cell lung cancer.  Crit Rev Oncol Hematol. 2002;  41 57-77
• 15 Chan T O, Rittenhouse S E, Tsichlis P N. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation.  Annu Rev Biochem. 1999;  68 965-1014
• 16 Engebraaten O, Bjerkvig R, Pedersen P H et al.. Effects of EGF, bFGF, NGF and PDGF (bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro.  Int J Cancer. 1993;  53 209-214
• 17 Lammering G, Hewit T H, Hawkins W T et al.. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization.  J Natl Cancer Inst. 2001;  93 921-929
• 18 Fujino S, Enokibori T, Tezuka N et al.. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer.  Eur J Cancer. 1996;  32A 2070-2074
• 19 Salomon D S, Brandt R, Ciardiello F et al.. Epidermal growth factor-related peptides and their receptors in human malignancies.  Crit Rev Oncol Hematol. 1995;  19 183-232
• 20 Veale D, Kerr N, Gibson G J et al.. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival.  Br J Cancer. 1993;  68 162-165
• 21 Pavelic K, Banjac Z, Pavelic J et al.. Evidence for a role of EGF receptor in the progression of human lung carcinoma.  Anticancer Res. 1993;  13 1133-1137
• 22 Swinson D E, Cox G, Jones J L et al.. Activated epidermal growth factor receptor (EGFR) correlates with a poor prognosis in non-small cell lung cancer (NSCLC) [abstract 1208].  Proc Am Soc Clin Oncol. 2002;  21 303a
• 23 Bowers G, Reardon D, Hewitt T et al.. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells.  Oncogene. 2001;  20 1388-1397
• 24 Herbst R S, Shin D M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy.  Cancer. 2002;  94 1593-1611
• 25 Mendelsohn J, Dinney C P. The Willet F. Whitmore, Jr. Lectureship: blockade of epidermal growth factor receptors as anticancer therapy.  J Urol. 2001;  165 1152-1157
• 26 Shin D M, Nemunaitis J, Zinner R G et al.. A phase I clinical and biomarker study of CI-1033, a novel pan-ErbB tyrosine kinase inhibitor in patients with solid tumors [abstract 324].  Proc Am Soc Clin Oncol. 2001;  20 82a
• 27 Wakeling A E, Barker A J, Davies D H et al.. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines.  Breast Cancer Res Treat. 1996;  38 67-73
• 28 Ciardiello F, Caputo R, Bianco R et al.. Antitumor effect and potential of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.  Clin Cancer Res. 2000;  6 2053-2063
• 29 Woodburn J R, Barker A J, Wakeline A E et al.. 6-amino-4 (3-methyl-phenylamino): an EGF receptor tyrosine kinase inhibitor with activity in a range of human tumor xenografts.  Proc Am Assoc Cancer Res. 1996;  36 390
• 30 Woodburn J R, Barker A J, Gibson K H et al.. ZD 1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development.  Proc Am Assoc Cancer Res. 1997;  38 633
• 31 Albanell J, Rojo F, Averbuch S et al.. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.  J Clin Oncol. 2002;  20 110-124
• 32 Raben D, Helfrich B A, Chan D et al.. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.  Semin Oncol. 2002;  29(suppl 4) S37-S46
• 33 Sirotnak F M, Zakowski M F, Miller V A et al.. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.  Clin Cancer Res. 2000;  6 4885-4892
• 34 Baselga J, Rischin D, Ranson M et al.. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.  J Clin Oncol. 2002;  20 4292-4302
• 35 Kris M, Herbst R et al.. Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD 1839 (Iressa), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR).  Lung Cancer. 2000;  29(suppl 1) S72
• 36 Kelly H, Ferry D et al.. ZD 1839 (Iressa) an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): pharmacokinetics in a phase I study of patients with advanced cancer.  Proc Am Assoc Cancer Res. 2000;  41
• 37 Kris M G, Natale R B, Herbst R S et al.. A phase II trial of ZD1839 (“Iressa”) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2) [abstract 1166].  Proc Am Soc Clin Oncol. 2002;  21 292a
• 38 Fukuoka M, Yano S, Giaccone G et al.. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer.  J Clin Oncol. 2003;  21 2237-2246
• 39 Natale R B, Skarin A, Maddox A-M et al.. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 (“Iressa”) in IDEAL 2 [abstract 1167].  Proc Am Soc Clin Oncol. 2002;  21 292a
• 40 Douillard J-Y, Giaccone G, Horai T et al.. Improvement in disease-related symptoms and quality of life in patients with advanced non-small cell lung cancer (NSCLC) treated with ZD1839 (“Iressa”) (IDEAL 1) [abstract 1195].  Proc Am Soc Clin Oncol. 2002;  21 299a
• 41 Giaccone G, Johnson D H, Manegold C et al.. A phase III clinical trial of ZD 1839 (“Iressa”) in combination with gemcitabine and cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer (INTACT 1).  Proc Eur Soc Med Oncol. 2002;  13(suppl 5) S2
• 42 Johnson D H, Herbst R, Giaccone G et al.. ZD 1839 (“Iressa”) in combination with paclitaxel and carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2).  Proc Eur Soc Med Oncol. 2002;  13(suppl 5) S127
• 43 Pollack V A, Savage D M, Baker D A et al.. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.  J Pharmacol Exp Ther. 1999;  291 739-748
• 44 Moyer J D, Barbacci E G, Iwata K K et al.. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.  Cancer Res. 1997;  57 4838-4848
• 45 Budillon A, Di Gennaro E, Barbarino M et al.. ZD 1839, an epidermal growth factor receptor tyrosine kinase inhibitor, upregulates p27^KIP1 inducing G1 arrest and enhancing the antitumor effect of interferon.  Proc Am Assoc Cancer Res. 2000;  41 773
• 46 Iliakis G. Cell cycle regulation in irradiated and nonirradiated cells.  Semin Oncol. 1997;  24 602-615
• 47 Perez-Soler R, Chachoua A, Huberman M et al.. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC) [abstract 1235].  Proc Am Soc Clin Oncol. 2001;  20 310a
• 48 Lynch D H, Yang X D. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment.  Semin Oncol. 2002;  29(suppl 4) S47-S50
• 49 Prewett M, Rockwell P, Rockwell R F et al.. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma.  J Immunother Emphasis Tumor Immunol. 1996;  19 419-427
• 50 Raben D, Helfrich B, Chan D et al.. C225 anti-EGFR antibody potentiates radiation (RT) and chemotherapy (CT) cytotoxicity in human non-small cell lung cancer (NSCLC) cells in vitro and in vivo [abstract 1026].  Proc Am Soc Clin Oncol. 2001;  20 257a
• 51 Baselga J, Pfister D, Cooper M R et al.. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.  J Clin Oncol. 2000;  18 904-914
• 52 Kim E S, Mauer A M, Fossella F V et al.. A phase II study of Erbitux (IMC-225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC) [abstract 1168].  Proc Am Soc Clin Oncol. 2002;  21 293a
• 53 Figlin R A, Belldegrun A S, Crawford J et al.. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase I clinical results [abstract 35].  Proc Am Soc Clin Oncol. 2002;  21 10a